Do not you hear the audio? Click  

 



Pre-congress PK/PD workshop
Pre-congress PK/PD workshop (14:00~17:00, April 5, 2011 )
 
Contents Background of PK/PD-
Johan Mouton
     Canisius Wilhelmina Hospital, The Netherlands
n-vitro methodology (pros and cons of MIC, static time-kill, open dynamic model, hollow-fiber model)
Vincent Tam     University of Houston, USA
Animal infection models [(non-)neutropenic, various approaches to PK modification, site of infection vs drug concentration, protein binding]
Johan Mouton     Canisius Wilhelmina Hospital, The Netherlands
Clinical applications (population PK, PK/PD targets for various outcomes, monte carlo simulations)
Vincent Tam     University of Houston, USA

 

Day 1   April 6, 2011
Major Resistant Pathogens
Session 1
STREPTOCOCCUS PNEUMONIAE :
ARE WE OVERCOMING PNEUMOCOCCAL RESISTANCE?
Chairperson : Nancy Henry (USA), Celia Carlos (The Philippines)
Session 1 Changing epidemiology of pneumococcal diseases in the post-vaccine era
Ron Dagan     Soroka University Medical Center, Israel
In vitro pneumococcal resistance : what does it mean in the clinical practice ?
Donald Low     Mount Sinai Hospital, Canada
Role of Streptococcus pneumoniae in the era of pandemic influenza
Keith Klugman     Emory University, USA
 
Session 2
MRSA IN THE HOSPITAL AND THE COMMUNITY : THE RETURN OF THE KING
Chairperson : Keiichi Hiramatsu (Japan), Kang Won Choe (Korea)
Session 2 Nosocomial MRSA : the classic threat in the hospital continues
Hui Wang
    Peking University People's Hospital, P.R. China
Community-associated MRSA : a clear and present danger
Keryn Christiansen     Royal Perth Hospital, Australia
SCCmec : diversity and evolution
Teruyo lto    
Juntendo Univesity, Japan
Treatment options for MRSA infections
Robert Moellering     Harvard Medical School, USA
 
Session 3
ESBLS, AMPCS & CARBAPENEMASES IN ENTEROBACTERIACEAE
Chairperson : David Paterson (Australia), Bong Suk Shim (Korea)
Session 3 Global threat of KPC carbapenemase
Karen Bush    
Indiana University, USA
Emergence of non-KPC carbapenemase : NDM and more
David Livermore    
Health Protection Agency, UK
Current status of ESBLs and AmpCs : clinical implications & treatment options
Po-Ren Hsueh     National Taiwan University Hospital, Taiwan
 
Session 4
MAJOR ISSUES OF RESISTANCE IN THE ASIA PACIFIC REGION : AN EPICENTER OF RESISTANCE
Chairperson : Moon Won Kang (Korea), Byung Guk Yang (Korea)
Session 4 Major resistance problem in China
Minggui Wang     Huashan Hospital, Fudan University, P.R. China
Major resistance problem in India
V. Ramasubramanian     Apollo Hospital, India
Major resistance problem in Southeast Asia
Visanu Thamlikitku    l
Mahidol University, Thailand
Major resistance problem in Far East Asia
Shigefumi Maesaki     Saitama University, Japan
     
Session 5
CLINICAL MICROBIOLOGY LAB : WHAT'S NEW IN THE FUTURE ?
Chairperson : Donald Low (Canada), Eui-Chong Kim (Korea)
Session 5 Antimicrobial susceptibility testing : improved detection of beta lactam resistance
Mary Jane Ferraro     Massachusetts General Hospital, USA
Genetic detection of antimicrobial resistance : an update
Franklin Cockerill     Mayo Clinic, USA
Advanced technologies to identify pathogens : what's new?
Keryn Chirstiansen     Royal Perth Hospital, Australia
 
Session 6
MDR, XDR & PDR Gram-negative non-fermenters
Chairperson : Donald Low (Canada), Eui-Chong Kim (Korea)
Session 6 MDR in MBLs-producers
David Paterson     University of Queensland, Australia
MDR in OXA carbapenemases-producers
Kyungwon Lee     Yonsei University, Korea
Clinical implication and treatment options for MDR PDRAcinetobacter
Matthew E. Falagas     Alfa Institute of Biomedical Sciences, Greece
     
PLENARY KEYNOTE LECTURE
ANTIMICROBIAL RESISTANCE IN THE ERA OF ANTIBIOTICS
Chairperson : Jong Koo Lee (Korea)
PL1 Evolution of antimicrobial resistance : what will happen in the bugs ?
David Livermore     Health Protection Agency, UK
 
MERLE SENDE MEMORIAL LECTURE
ANTIMICROBIAL TREATMENT IN THE ERA OF ANTIBIOTIC RESISTANCE
Chairperson : Walter Wilson (USA)
PL2 Antimicrobial combination therapy in the era of multidrug resistance : how does it work ?
Robert Moellering     Harvard Medical School, USA
 
PLENARY KEYNOTE LECTURE
PREVENTION AND CONTROL OF RESISTANCE : VACCINATION
Chairperson : Victor Lim (Malaysia)
PL3 Developing vaccines for the poor : the IVI experience
Cecil Czerkinsky     International Vaccine Institute
 
Interactive Session 1
 
  Treatment of infection by MDR Gram-positive infections :
MDR pneumococci, MRSA, VRE infections
Robin Patel     Mayo Clinic, USA
Walter Wilson    
Mayo Clinic, USA
Donald Low
    Mount Sinai Hospital, Canada

 

Day 2   April 7, 2011
Prevention and Control of Resistance
Session 7
NEW VACCINES ON THE HORIZON
Chairperson : Hoan Jong Lee (Korea), Jin Han Kang (Korea)
Session 7 Vaccines against enteric infections : cholera, typhoid and shigellosis
Nitin Shah     Hinduja Hospital, India
Pneumococcal vaccines : past, present and future
Keith Klugman     Emory University, USA
Rotavirus vaccine
Paul Kilgore    
International Vaccine Institute
 
Session 8
ANTIBIOTIC STEWARDSHIP : WHERE ARE WE NOW ?
Chairperson : Ian Gould (UK), Po-Ren Hsueh (Chinese Taipei)
Session 8 What resistance means to the prescribers
Ian Gould     Aberdeen Royal Infirmary, UK
Antimicrobial stewardship in Asian countries
Victor Lim    
International Medical University, Malaysia
Antimicrobial stewardship in European countries
Stephan Harbarth
    Geneva University Hospital, Switzerland
Antimicrobial stewardship in USA: How to "Get Smart" ?
Lauri Hicks     CDC, USA

 
Session 9
PEDIATRIC INFECTIONS
Chairperson : Yonghong Yang (P.R. China), Sung Hee Oh (Korea)
Session 9 Childhood pneumonia: a global perspective
Nancy Henry     Mayo Clinic, USA
What's new in pediatric enteric infections?
Cheng-Hsun Chiu    
Chang Gung Children's Hospital, Taiwan
Otitis media: a contiuning problem in the era of resistance
Ron Dagan     Soroka University Medical Center, Israel
Respiratory Virus Infection in High-Risk Children
Yae-Jean Kim    
Samsung Medical Center, Korea
 
Session 10
EXPERIMENTAL VACCINES FOR THE FUTURE
Chairperson : Keith Klugman (USA), Duk Hyoung Lee (Korea)
Session 10 Vaccines in the 21st century: whats' next?
Margaret Liu
    ProTherImmune, USA
Staphylococcal vaccine: where are we now?
Douglas Girgenti     Pfizer Inc., USA
The Holy Grail: Universal Vaccines for Influenza?
Leo Poon    
University of Hong Kong, Hong Kong, SAR
HIV/AIDS vaccine
Margaret Liu     ProTherImmune, USA
     
Session 11
PK/PD
Chairperson : Johan Mouton (The Netherlands), June Hee Woo (Korea)
Session 11

The use of beta-lactamase inhibitors to reconquer resistance
Johan Mouton     Canisius Wilhelmina Hospital, The Netherlands

Old drugs, new uses and the pitfalls in between
John Turnidge    
Women's & Children's Hospital, Australia
How can we improve the use of new lipopeptides
Vincent Tam    
University of Houston, USA
PK/PD of colistin and clinical outcomes of MDR gram negative infections
Visanu Thamlikitkul     Mahidol University, Thailand
 
Session 12
ANTIMICROBIAL RESISTANCE IN ANIMALS
Chairperson : Yong Ho Park (Korea), Hamimah Hassan (Malaysia)
Session 12 Emerging antimicrobial resistant pathogens in animals
Yong Ho Park    
Seoul National University, Korea
Risk assessment for antimicrobial use in food animals
Tom Shryock     Elanco Animal Health, USA
Risk management interventions of resistance in animals
H. Scott Hurd    
Iowa State University, USA
     
PLENARY KEYNOTE LECTURE
MAJOR RESISTANT PATHOGEN AND ITS MECHANISM
Chairperson : Robert Moellering (USA)
PL4 Methicilin-resistant Staphylococcus aureus : a comprehensive view
Keiichi Hiramatsu     Juntendo University, Japan
 
PLENARY KEYNOTE LECTURE
PREVENTION AND CONTROL OF RESISTANCE : INTERNATIONAL COLLABORATION
Chairperson : Walter Wilson (USA)
PL5 International initiatives to control antimicrobial resistance : "I care" project
Jae-Hoon Song    
Samsung Medical Center, Korea
 
PLENARY KEYNOTE LECTURE
MAJOR RESISTANCE ISSUES IN THE 21ST CENTURY
Chairperson : David Livermore (UK)
PL6 XDR & PDR Gram-negative bacilli : an extreme model of resistance
Mattew Falagas     Alfa Institute of Biomedical Sciences, Greece
 
Interactive Session 2
 
  Treatment of infection by MDR Gram-negative infections : PDR Acinetobacter pneumonia, Carbapenemase-producing K. pneumoniae bacteremia
David Paterson     University of Queensland, Australia
Franklin Cockerill    
Mayo Clinic, USA
Matthew Falagas    
Alfa Institute of Biomedical Sciences, Greece

 

Day 3   April 8, 2011
Treatment of Major Infections
Session 13
CLINICAL CHALLENGES IN MYCOLOGY (Interactive Session)
Chairperson : Thomas Patterson (USA)
Session 13 Cases of invasive fungal infections : candidiasis, aspergillosis, cryptococcosis
Thomas Patterson     University of Texas Health Science Center at San Antonio, USA
David Ellis     Women's and Children's Hospital, Australia
Monica Slavin Royal     Melbourne Hospital, Australia
Boonmee Sathapatayavongs    
Mahidol University, Thailand
 
Session 14
EMERGENCY PREPAREDNESS FOR PANDEMICS, BIOTERRORISM OR EMERGING INFECTIONS
Chairperson : Victor Lim (Malaysia), Min Ja Kim (Korea)
Session 14 Lessons from SARS and H1N1
Thomas So     Princess Margaret Hospital, Hong Kong, SAR
Emering pathogens as a threat for future pandemics
Donald Low     Mount Sinai Hospital, Canada
Contingency planning: how does healthcare facilities survive?
Walter Wilson     Mayo Clinic, USA
 
Session 15
NEW ANTIMICROBIAL AGENTS ON THE HORIZON
Chairperson : Chang Yong Cha (Korea), David Livermore (UK)
Session 15 New antibiotics mainly against resistant Gram-positives
Robin Patel    
Mayo Clinic, USA
New antibiotics mainly against resistant Gram-negatives
David Paterson     University of Queensland, Australia
New uses of old antibiotics: recycling works
John Turnidge    
Women's & Children's Hospital, Australia
 
Session 16
TREATMENT OF HIV/AIDS (INTERACTIVE SESSION)
Chairperson : June Myung Kim (Korea)
Session 16 Case : Immune reconstitution inflammatory syndrome in HIV patients
Myoung-Don Oh     Seoul National University, Korea
Case : Antiretroviral therapy for the HIV patients with adverse reactions due to antiretroviral agents
Patrick Chung Ki Li     Queen Elizabeth Hospital, Hong Kong
Case : Antiretroviral therapy for the HIV patients with antiretroviral resistance
Koya Ariyoshi    
Nagasaki University, Japan
     
Session 17
INFECTION CONTROL OF RESISTANT PATHOGENS
Chairperson : Wing Hong Seto (Hong Kong), Kyungwon Lee (Korea)
Session 17 Infection control of MDR Gram-negaive bacilli : practical approaches
Wing Hong Seto     Queen Mary Hospital, Hong Kong, SAR
Control of MRSA in the hospital: Is it really possible?
Stephan Harbarth     Geneva University Hospital, Switzerland
Application of antimicrobial stewardship and infection control program to control PDR-A. baumannii in resource-limited setting
Anucha Apisarnthanarak
    Thammasart University Hospital, Thailand
 
Session 18
TREAMENT OF MDR & XDR TUBERCULOSIS
Chairperson : Visanu Thamlikitkul (Thailand), O Jung Kwon (Korea)
Session 18 Global epidemiology of MDR & XDR tuberculosis
Chen-Yuan Chiang     International Union Against Tuberculosis and Lung Disease
Mechanism of drug resistance in M. tuberculosis
Ying Zhang     Johns Hopkins University, USA
Treatment of MDR & XDR tuberculosis
Wing Wai Yew
    Grantham Hospital, Hong Kong, SAR
     
PLENARY KEYNOTE LECTURE
TREATMENT OF MAJOR INFECTIONS
Chairperson : Franklin Cockerill (USA)
PL7 Treatment of implantable cardiac device infections : a clinical dilemma in the era of resistance
Walter Wilson     Mayo Clinic, USA
 
PLENARY KEYNOTE LECTURE
TREATMENT OF MAJOR INFECTIONS
Chairperson : Robin Patel (USA)
PL8 Discovery of novel antibacterial agents : Looking back, Moving forward
Karen Bush     Indiana University, USA